Clinical Trial Update: Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety, tolerability and immunogenicity of Bavarian Nordic's Recombinant MVA BN RSV Vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• Recombinant MVA BN RSV Vaccine

Snippet

Sponsor: Bavarian Nordic | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED